Hasil Pencarian  ::  Simpan CSV :: Kembali

"Agen penghambat beta telah menunjukkan penurunan resiko perawatan atau kematian pasien dengan gagal jantung ringan sampai sedang, tetapi hanya sedikit diketahui mengenai manfaat atau keamanan agen ini pada gagal jantung berat. Dilaporkan satu kasus penggunaan penghambat beta pada gagal jantung berat dengan fraksi ejeksi kurang dari 25%. Laporan manfaat penghambat beta terhadap kesakitan dan kematian pasien dengan gagal jantung ringan sampai sedang juga ditemukan pada pasien dengan gagal jantung berat seperti yang dilaporkan pada kasus ini. (Med J Indones 2002; 11: 174-5)

---

Beta-blocking agents have been shown to reduce the risk of hospitalization and death in patients with mild to moderate heart failure, but little is known about the efficacy or safety of these agents in severe heart failure. A case of beta blocker administration in severe heart failure with ejection fraction less than 25% is reported. The reported benefits of beta blockers with regard to morbidity and mortality in patients with mild to moderate heart failure were also found in the patient with severe heart failure as reported in this case. (Med J Indones 2002; 11: 174-5)"

"Latar Belakang : Rasio netrofil-limfosit (NLR) sudah banyak diteliti memiliki hubungan yang erat dengan luaran penyakit kardiovaskular. Hal ini berhubungan dengan proses inflamasi yang dapat menyebabkan perubahan struktural dan fungsi dari jantung yang dapat dinilai dengan salah satunya fraksi ejeksi (EF). Pasien IMA-EST yang mendapatkan IKPP memiliki resiko untuk mengalami perubahan EF yang berhubungan dengan NLR saat admisi.Tujuan : Mengetahui hubungan antara NLR rendah dengan peningkatan fraksi ejeksi (EF) ventrikel kiri pada pasien IMA-EST yang mendapatkan IKPP.Metode : Desain penelitian ini adalah kohort retrospektif dan data dilaporkan dalam bentuk deskriptif dan analitik korelasi. Dilakukan analisa hubungan NLR admisi pasien STEMI yang mendapatkan IKPP dengan EF ≤50% yang di ambil dengan ekokardiografi selama perawatan, akan kemudian dilakukan ekokardiografi kembali pada bulan ke-3.Hasil : Total sampel penelitian adalah 58 subjek dengan 91,4% merupakan laki-laki. Rerata nilai EF I 42% dan EF ke-2 45,9%. Pasien dibagi menjadi 2 kelompok dengan NLR <7 dan >7. Terdapat perbedaan proporsi antara kedua kelompok yang ditunjukan dengan nilai p sebesar 0,05. Subjek yang mempunyai kadar NLR >7 lebih beresiko sebesar 4,30x untuk tidak mengalami perbaikan. Faktor yang paling dominan yang mempengaruhi perbaikan EF pada penelitian ini adalah NLR <7 dengan OR sebesar 6,56 (1,31-32,84) setelah dikontrol oleh variable lekosit dan multivesel diseases.Kesimpulan : Terdapat hubungan antara NLR dengan perbaikan EF ventrikel kiri pada Pasien IMA-EST yang mendapatkan IKPP

---

Background : The neutrophil-lymphocyte ratio (NLR) has been widely studied to have a close relationship with cardiovascular disease outcomes. This is related to the inflammatory process that can cause structural and functional changes of the heart which can be assessed by ejection fraction (EF). STEMI patients who receive Primary PCI are at risk for experiencing changes in EF related to NLR at admission.

Objective: To determine the relationship between low NLR and increased left ventricular ejection fraction (EF) in STEMI patients who receive primary PCI.

Methods: The design of this study was a retrospective cohort and the data were reported in descriptive and analytic form. An analysis of the relationship between NLR admissions for STEMI patients who received primary PCI with an EF 50% or below were carried out by echocardiography during treatment, then echocardiography was performed again in the 3rd month.

Results: The total sample of the study ware 58 subjects with 91.4% of males. The mean score for EF I was 42% and EF 2 was 45.9%. Patients were divided into 2 groups with NLR <7 and >7. There is a difference in the proportion between the two groups as indicated by a p-value of 0.05. Subjects who have NLR levels > 7 are 4,30x more at risk for not experiencing improvement. The most dominant factor influencing the improvement of EF in this study was NLR <7 with an OR of 6.56 (1.31-32.84) after being controlled by leukocyte and multivesel diseases variables.

Conclusion: There is a relationship between NLR and left ventricular EF improvement in IMA-EST patients who received PCI"

"Latar belakang: Hiperfosfatemia pada penyakit ginjal kronik (PGK) terjadi akibat kegagalan ginjal dalam mengekskresi fosfat, tingginya asupan fosfat atau peningkatan pelepasan fosfat dari ruang intraselular. Hipertrofi ventrikel kiri (left ventricle hypertrophy/LVH) adalah perubahan jantung yang umum terjadi dan menjadi tanda awal penyakit kardiovaskular pada anak dengan PGK. Penelitian ini bertujuan untuk menilai hubungan antara kadar fosfat darah dengan fungsi sistolik serta penebalan ventrikel kiri jantung pada pada pasien anak penyakit ginjal kronik tahap akhir. Metode: Penelitian ini merupakan studi potong lintang di RSUPN dr. Cipto Mangunkusumo Jakarta terhadap anak PGTA tanpa ada kelainan jantung bawaan dari april-mei 2024 dengan dilakukan pemeriksaan fosfat darah dan ekokardiografi. Hasil: Terdapat 56 subyek dengan titik potong kadar fosfat darah 7,35 mg/dL. Didapatkan penurunan fungsi fraksi ejeksi dengan rasio prevalens pada pasien dengan hiperfosfatemia adalah 3,895 dengan IK 95% antara 2,552-9,773 (p = 0,002) serta kecenderungan hubungan kadar fosfat dengan penebalan LVMI (p = 0,680) dan disfungsi diastolik jantung kiri (p = 0,145). Kesimpulan: Terdapat hubungan antara kadar hiperfosfemia darah dengan fungsi sistolik pada pasien anak penyakit ginjal kronik tahap akhir. Tetapi tidak terdapat hubungan dengan peningkatan massa ventrikel kiri jantung dan diastolik jantung.

---

Background: Hyperphosphatemia in chronic kidney disease (CKD) occurs due to renal failure to excrete phosphate, high phosphate intake or increased phosphate release from the intracellular space. Left ventricle hypertrophy (LVH) is a common heart change and an early sign of cardiovascular disease in children with CKD. This study aimed to assess the relationship between blood phosphate levels to decreased systolic and diastolic function and thickening of the left ventricle in pediatric patients with end-stage chronic kidney disease. Method: This was a cross-sectional observational study at RSUPN dr. Cipto Mangunkusumo Jakarta with PGTA children without congenital heart defects. Paremeters for function and LVM were assessed by Doppler echocardiography and blood phosphate examination. Results: There were 56 subjects with a cut point for blood phosphate levels of 7.35 mg/dL. It was found that a decrease in ejection fraction function with a prevalence ratio in patients with hyperphosphatemia was 3.895 with a 95% CI between 2.552-9.773 (p = 0.002) as well as a trend in the relationship between phosphate levels and LVMI thickening (p = 0.680) and left heart diastolic dysfunction (p = 0.145) Conclusion: There is association between blood levels of phosphemia and systolic function in pediatric patients with end-stage chronic kidney disease. However, there is no association with increased left ventricular mass index and dyastolic function."

"Latar Belakang : Disfungsi ventrikel kanan merupakan prediktor mortalitas dan morbiditas terburuk  pada pasien dengan hipertensi pulmonal (HP) prekapiler yang independen terhadap resistensi vaskular paru (RVP). Berbagai studi telah membuktikan bahwa pemberian penghambat oksidasi asam lemak seperti trimetazidine dapat memperbaiki fungsi ventrikel kanan pada hewan coba HP prekapiler. Oleh karena itu, kami berhipotesa bahwa terapi trimetazidine dapat memperbaiki fungsi ventrikel kanan pada pasien HP prekapiler.Tujuan Penelitian : Mengetahui efek trimetazidine terhadap fungsi ventrikel kanan pasien HP prekapiler.Metode Penelitian : Penelitian ini merupakan studi eksperimental acak tersamar ganda. Sampel diambil secara acak dari populasi terjangkau pasien HP prekapiler yang berobat di poliklinik Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPDHK). Pasien yang memenuhi kriteria inklusi dan eksklusi akan mendapatkan tablet trimetazidine atau plasebo selama 3 bulan diatas terapi standar HP. Pasca terapi, kedua grup akan dilakukan evaluasi terhadap luaran berupa perubahan fungsi ventrikel kanan yang diukur melalui MRI kardiak pada bulan ke-3.Hasil : Terdapat 26 subjek penelitian HP prekapiler diikutsertakan dalam penelitian ini dan dirandomisasi ke dalam grup plasebo atau trimetazidine. Sebanyak 10 pasien grup trimetazidine dan 10 pasien grup plasebo berhasil menjalani proses penelitian sampai selesai. Didapatkan perbaikan fungsi fraksi ejeksi ventrikel kanan (FEVKA) secara bermakna pada grup trimetazidine 3.87+1.5% dibandingkan dengan grup plasebo -2.76+1.6% (p0.008, IK 1.96-10.96). Terdapat pula perbaikan kapasitas fungsional secara bermakna pada grup trimetazidine 0.24+0.09 dibandingkan dengan plasebo -0.44+0.16 (p 0.002, IK 0.28 s/d 1.08).Kesimpulan : Terdapat perbaikan fungsi FEVKA dan kapasitas fungsional secara bermakna pasca terapi trimetazidine selama 3 bulan dibandingkan dengan plasebo diatas terapi standar HP yang sudah rutin dikonsumsi.

---

RATIONALE: Right ventricular dysfunction is the worst mortality predictor in pulmonary arterial hypertension (PAH). Recent animal PAH studies have demonstrated the benefit of partial fatty acid inhibitor such as trimetazidine in improving right ventricular function. Therefore, we hypothesize that trimetazidine can improve right ventricular ejection fraction (RVEF) in PAH patients.

OBJECTIVE : Investigating the effect of  trimetazidine on right ventricle function in PAH patients.

METHODS: We conducted 3 months randomized double blind placebo controlled trial on PAH patients at outpatient clinic in National Cardiovascular Center Harapan Kita Hospital Indonesia. Those who fulfilled the inclusion criteria will be randomized into trimetazidine or placebo group for 3 months on top of their standard PAH regime. The primary outcome of this study is the differences of RVEF.

MEASUREMENT AND MAIN RESULTS: We randomly enrolled 26 PAH patients equally to receive placebo or trimetazidine for 3 months on top of their standard PAH regime. Total of 10 patients in each group was able to finish the study. There was significant improvement of RVEF in trimetazidine group 3.78+1.5% compared to placebo 2.76+1.6% (p 0.008, CI 1.96 to 10.96). Furthermore, we also observed improvement of functional capacity in trimetazidine group 0.24+0.09 compared to placebo -0.44+0.16 (p 0.002, CI 0.28 s/d 1.08).

CONCLUSIONS: Trimetazidine therapy for 3 months on top of standard PAH regime significantly improve RVEF and functional capacity in PAH patients."

"Latar Belakang: Fibroblast Growth Factor-23 (FGF-23) merupakan penanda proses gangguan mineral tulang pada penyakit ginjal kronik dialisis. Peningkatan FGF-23 menyebabkan proses remodelling yang berkontribusi pada perkembangan hipertrofi ventrikel kiri (LVH) dan penurunan fraksi ejeksi ventrikel kiri (LVEF) secara langsung pada pasien hemodialisis masih kontroversi.Tujuan: Mengetahui hubungan kadar FGF-23 dalam serum dengan hipertrofiventrikel kiri dan fraksi ventrikel kiri pada pasien hemodialisis regular.Metode: Studi potong lintang terhadap 111 pasien hemodialisis regular dua kali seminggu di Rumah sakit Cipto Mangunkusumo Jakarta selama periode Juli sampai September 2023. Dilakukan Uji Mann Whitney dan Chi Square untuk menilai perbedaan serta hubungan kadar FGF-23 dengan hipertrofi ventrikel kiri (LVH) dan fraksi ejeksi ventrikel kiri (LVEF).Hasil: Dari 111 subjek yang diikutsertakan pada analisis didapatkan median usia subjek yaitu 51 (37-61) tahun, kadar rerata iFGF-23 536,2 pg/ml (min-max 1358-2180,1). Didapatkan hasil echocardiography gambaran LVH sebesar 84,68% dan LVEF yang turun 10,81% . Didapatkan perbedaan (terbalik) kadar FGF-23 antara LVH dengan Tidak LVH (p value 0,003). Didapatkan hubungan (terbalik) kadar FGF-23 dengan LVH p value 0,010 PR (95%IK) 0,792 (0,663-0946). Tidak didapatkan perbedaan kadar FGF-23 antara yang mengalami penurunan LVEF dengan LVEF normal.Kesimpulan: Terdapat perbedaan (terbalik) kadar FGF-23 antara hipertrofi ventrikel kiri dengan tidak hipertrofi ventrikel kiri namun tidak terdapat perbedaan kadar FGF-23 antara yang mengalami penurunan fraksi ejeksi ventrikel kiri dengan yang tidak mengalami penurunan fraksi ejeksi ventrikel kiri.

---

Background: Fibroblast Growth Factor-23 (FGF-23) is a marker that indicate the process of bone mineral disorders in chronic kidney disease dialysis. An elevated FGF-23 causes a remodeling process that contributes to the development of left ventricle hypertrophy (LVH) and the still controversial direct decline of left ventricle ejection fraction (LVEF) among hemodialysis patients.

Objective: To seek out the connection between FGF-23 levels in serum with left ventricle hypertrophy and left ventricle ejection fraction among regular hemodialysis patients.

Methods: It is a cross-sectional study conducted to 111 regular hemodialysis patients for twice a week in Cipto Mangunkusumo Hospital in Jakarta from July to September 2023. The Mann Whitney and Chi Square tests were subsequently used to evaluate the difference as well as the connection between FGF-23 levels with left ventricle hypertrophy (LVH) and left ventricle ejection fraction (LVEF).

Results: Of the 111 subjects included in the analysis, the median age of the subject was 51 (37-61) years, show an average level of iFGF-23 value at 536.2 pg/ml (min-max 1358-2180.1). Results obtained from the echocardiography images show that 84,68% had LVH Meanwhile, LVEF results of decline was 10,81%. There is a difference (reverse) in FGF-23 levels between patients with LVH and patients without LVH (p value 0.003). Furthermore, there is a correlation (reverse) between FGF-23 levels with LVH p value 0.010 PR (CI 95%) 0.792 (0.663-0.946). Nonetheless, there is no difference between the levels of FGF-23 between subjects who experienced LVEF decline and those who did not experience LVEF normal.

Conclusion: There is a difference (reverse) in FGF-23 levels between subjects with LVH and those without LVH. However, there is no difference in FGF-23 levels among those who experienced left ventricle ejection fraction (LVEF) decline and those who did not experience LVEF decline."

"Doksorubisin masih banyak digunakan di Rumah Sakit Kanker Dharmais. Efek samping doksorubisin terhadap jantung yang dapat ditandai dengan adanya penurunan fraksi ejeksi ventrikel kiri perlu mendapatkan perhatian khusus. Penelitian ini bertujuan untuk memperoleh faktor-faktor risiko yang mempengaruhi penurunan fraksi ejeksi ventrikel kiri pada pasien kanker yang mendapatkan kemoterapi doksorubisin di Rumah Sakit Kanker Dharmais. Penelitian dilakukan menggunakan rancangan cross sectional. Data diperoleh dari rekam medis pasien. Populasi adalah pasien kanker yang mendapatkan kemoterapi doksorubisin periode Oktober 2011-Oktober 2013 di Rumah Sakit Kanker Dharmais. Sampel yang memenuhi kriteria inklusi dan ekslusi sebanyak 77 pasien. Faktor-faktor risiko yang dievaluasi adalah jenis kelamin, usia, kombinasi kemoterapi, hipertensi, diabetes mellitus, riwayat penyakit jantung, radiasi pada dada kiri dan penggunaan obat kardiotoksik lain. Penurunan fraksi ejeksi ventrikel kiri setelah kemoterapi doksorubisin terjadi pada 84,5% pasien: penurunan fraksi ejeksi <10% pada 48,1% pasien dan penurunan fraksi ejeksi ventrikel kiri ≥10% pada 36,4% pasien. Hipertensi berpengaruh terhadap penurunan fraksi ejeksi ventrikel kiri ≥10% secara bermakna (p=0,032). Jenis kelamin laki-laki dan radiasi pada dada kiri menunjukkan adanya kecenderungan berhubungan dengan penurunan fraksi ejeksi ventrikel kiri ≥10% (p=0,095 dan p=0,051). Penderita hipertensi yang mendapatkan doksorubisin berpotensi mengalami penurunan fraksi ejeksi ventrikel kiri.

---

Doxorubicin was still widely used in Dharmais Cancer Hospitals. The side effect of doxorubicin to the heart which can be characterized by a decline of left ventricular ejection fraction (LVEF) should received special attention. The aim of this study was to determine risk factors associated with the incidence of LVEF decline in cancer patients treated with doxorubicin at Dharmais Cancer Hospital. The study design was cross sectional. Data was collected from patient?s medical record. The populations were cancer patients who got doxorubicin on October 2011-October 2013 at Dharmais Cancer Hospital. The Samples which fulfilled the inclusion and exclusion criteria were 77 patients. Gender, age, chemotherapy combination, hypertension, diabetes mellitus, cardiac diseases history, left chest wall irradiation and the used of other drugs-induced cardiotoxicity were evaluated as risk factors. The amount of patient that declined their LVEF after doxorubicin chemotherapy was 84.5%, consist of 48.1% patients have ejection fraction fall <10%, and 36.4% patients have ejection fraction fall ≥10%. Hypertension significantly related with decline of LVEF ≥10% (p=0.032). Male sex and left chest wall irradiation showed a trend decline of LVEF ≥10% (p=0.095 and p=0.051). Patients with hypertension who got doxorubicin potentially had declined LVEF."

"[ABSTRAKLatar belakang dan tujuan: Menentukan korelasi nilai Ejection Fraction (EF) ventrikel kiri pada echo 2D dan DSCT jantung pada pasien Penyakit Jantung Koroner (PJK) stabil di RSUPN Cipto Mangunkusumo, sehingga nilai EF ventrikel kiri DSCT jantung dapat dijadikan acuan untuk evaluasi, penatalaksanaan dan prognosis pada PJK stabil yang mempunyai indikasi dilakukan CT jantung.Metode: Analisa retrospektif dari 30 pasien PJK stabil yang menjalani pemeriksaan echo 2D dan DSCT jantung dengan jarak waktu ≤ 3 bulan, meliputi penilaian EF ventrikel kiri. Berdasarkan nomor rekam medis yang ada, dilakukan pengambilan data EF ventrikel kiri echo 2D serta data tambahan lainnya. Nilai EF ventrikel kiri secara DSCT di evaluasi kembali pada cardiac workstation (Siemens, Leonardo), kemudian ditentukan bagaimana korelasinya dengan nilai EF ventrikel kiri secara echo 2D. Analisis statistik penelitian ini menggunakan uji SpearmanHasil: Terdapat perbedaan nilai EF ventrikel kiri sebanyak 4% antara echo 2D dengan DSCT jantung. Perbedaan sebanyak 4% ini tidak bermakna signifikan secara klinis namun bermakna secara statistik. Nilai R Spearman yang didapat adalah 0,17 sementara nilai p 0,364 (p > 0,005), artinya tidak terdapat korelasi antara nilai EF ventrikel kiri secara echo 2D dengan DSCT jantung pada pasien PJK stabil yang menjalani pemeriksaan echo 2D dan DSCT jantung dengan jarak ≤ 3 bulan di RSUPN Cipto Mangunkusumo.Kesimpulan: Walaupun pada penelitian ini secara statistik tidak berkorelasi, namun pada keadaan hasil echo yang borderlineatau pada pasien PJK stabil yang mempunyai indikasi dilakukan CT jantung, nilai EF ventrikel kiri pada CT dapat menjadi acuan untuk penatalaksanaan selanjutnya.

---

ABSTRACTBackground and Objectives: to determine the correlation left ventricle Ejection Fraction (EF) between echo 2D and cardiac DSCT in Coronary Heart Disease (CHD) patients at Cipto Mangunkusumo Hospital, so that the value of the left ventricular EF cardiac DSCT can be used as a reference for the evaluation, treatment and prognosis in stable CHD who have an indication of cardiac CT.Methods: A retrospective analysis of 30 patients with stable CHD who underwent 2D echo and cardiac DSCT with interval ≤ 3 months, include assessment of left ventricular EF. Based on the existing medical record number, performed data collection left ventricular EF 2D echo and other additional data. Value of left ventricular EF in DSCT in return on cardiac evaluation workstation (Siemens, Leonardo), then determined how its correlation with left ventricular EF values in 2D echo. Statistical analysis of this study using the Spearman test.Result: There are differences in left ventricular EF value by 4% between 2D echo with cardiac DSCT. The difference of 4% is not clinically significant, but statistically significant. Spearman R value obtained was 0.17 while the p-value 0.364 (p> 0.005), meaning that there is no correlation between the value of the left ventricular EF in 2D echo and cardiac DSCT in patients with stable CHD who underwent 2D echo and cardiac DSCT with distance ≤ 3 month in Cipto Mangunkusumo hospital.Conclusion: Although this study was not statistically correlated, but the results echo borderline or in stable CHD patients who had cardiac CT indications, left ventricular EF values on CT can be a reference for further management.;Background and Objectives: to determine the correlation left ventricle Ejection Fraction (EF) between echo 2D and cardiac DSCT in Coronary Heart Disease (CHD) patients at Cipto Mangunkusumo Hospital, so that the value of the left ventricular EF cardiac DSCT can be used as a reference for the evaluation, treatment and prognosis in stable CHD who have an indication of cardiac CT.Methods: A retrospective analysis of 30 patients with stable CHD who underwent 2D echo and cardiac DSCT with interval ≤ 3 months, include assessment of left ventricular EF. Based on the existing medical record number, performed data collection left ventricular EF 2D echo and other additional data. Value of left ventricular EF in DSCT in return on cardiac evaluation workstation (Siemens, Leonardo), then determined how its correlation with left ventricular EF values in 2D echo. Statistical analysis of this study using the Spearman test.Result: There are differences in left ventricular EF value by 4% between 2D echo with cardiac DSCT. The difference of 4% is not clinically significant, but statistically significant. Spearman R value obtained was 0.17 while the p-value 0.364 (p> 0.005), meaning that there is no correlation between the value of the left ventricular EF in 2D echo and cardiac DSCT in patients with stable CHD who underwent 2D echo and cardiac DSCT with distance ≤ 3 month in Cipto Mangunkusumo hospital.Conclusion: Although this study was not statistically correlated, but the results echo borderline or in stable CHD patients who had cardiac CT indications, left ventricular EF values on CT can be a reference for further management., Background and Objectives: to determine the correlation left ventricle Ejection Fraction (EF) between echo 2D and cardiac DSCT in Coronary Heart Disease (CHD) patients at Cipto Mangunkusumo Hospital, so that the value of the left ventricular EF cardiac DSCT can be used as a reference for the evaluation, treatment and prognosis in stable CHD who have an indication of cardiac CT.Methods: A retrospective analysis of 30 patients with stable CHD who underwent 2D echo and cardiac DSCT with interval ≤ 3 months, include assessment of left ventricular EF. Based on the existing medical record number, performed data collection left ventricular EF 2D echo and other additional data. Value of left ventricular EF in DSCT in return on cardiac evaluation workstation (Siemens, Leonardo), then determined how its correlation with left ventricular EF values in 2D echo. Statistical analysis of this study using the Spearman test.Result: There are differences in left ventricular EF value by 4% between 2D echo with cardiac DSCT. The difference of 4% is not clinically significant, but statistically significant. Spearman R value obtained was 0.17 while the p-value 0.364 (p> 0.005), meaning that there is no correlation between the value of the left ventricular EF in 2D echo and cardiac DSCT in patients with stable CHD who underwent 2D echo and cardiac DSCT with distance ≤ 3 month in Cipto Mangunkusumo hospital.Conclusion: Although this study was not statistically correlated, but the results echo borderline or in stable CHD patients who had cardiac CT indications, left ventricular EF values on CT can be a reference for further management.]"

"Latar belakang: Keputusan pasien untuk menjalani bedah pintas koroner dipengaruhi risiko mortalitas. Skor Age, Creatinine and Ejection Fraction ACEF merupakan prediktor mortalitas 30 hari pascabedah pintas koroner yang sederhana dan telah ditunjukkan memiliki performa yang setara dengan skor lain yang lebih kompleks. Tujuan: Menilai performa kalibrasi dan diskriminasi skor ACEF dalam memprediksi mortalitas 30 hari pascabedah pintas koroner di RSUPN Dr. Cipto Mangunkusumo RSCM. Metode: Penelitian ini merupakan studi kohort retrospektif terhadap pasien penyakit jantung koroner dewasa yang menjalani bedah pintas koroner di unit Pelayanan Jantung Terpadu PJT RSCM tahun 2013 ndash; 2015. Usia, kreatinin, dan fraksi ejeksi dinilai sebelum pasien menjalani bedah. Pasien diikuti hingga 30 hari pascabedah untuk dilihat outcome-nya meninggal atau tidak. Performa kalibrasi skor ACEF dinilai dengan uji Hosmer-Lemeshow dan plot kalibrasi. Performa diskriminasi skor ACEF dinilai dengan area under the curve AUC. Hasil: Sebanyak 308 subjek diikutsertakan dalam analisis. Performa kalibrasi skor ACEF dengan uji Hosmer-Lemeshow menunjukkan p=0,991 dan plot kalibrasi menunjukkan koefisien korelasi r=0,95. Performa diskriminasi skor ACEF ditunjukkan dengan nilai AUC sebesar 0,728 IK95 0,644; 0,811. Simpulan: Skor ACEF memiliki performa kalibrasi dan diskriminasi yang baik dalam memprediksi mortalitas 30 hari pascabedah pintas koroner di RSCM.

---

Background: The preference of patients to undergo coronary artery bypass grafting CABG surgery is influenced by the risk of mortality. Age, Creatinine and Ejection Fraction ACEF score is a simple predictor of 30 day mortality following CABG surgery and had been shown to be equivalent to more complex models.

Aim: To assess calibration and discrimination performance of ACEF score in predicting 30 day mortality following CABG surgery in Cipto Mangunkusumo Hospital.

Methods: This was a retrospective cohort study of adult coronary artery disease patients undergoing CABG surgery in Integrated Cardiovascular Center, Cipto Mangunkusumo Hospital between 2013 ndash 2015. Age, creatinine, and ejection fraction value were obtained before surgery. The subjects were followed up for up to 30 days postoperatively to assess the outcome dead or alive. Calibration performance were assessed by Hosmer Lemeshow test and calibration plot. Discrimination performance were assessed by the area under the curve AUC.

Results: A total of 308 subjects were included in analysis. Hosmer Lemeshow test of ACEF score showed p 0.991 and calibration plot showed r 0.95. Discrimination of ACEF score was shown by the AUC value of 0.728 95 CI 0.644 0.811.

Conclusion: ACEF score have a good calibration and discrimination performance in predicting 30 day mortality following CABG surgery in Cipto Mangunkusumo Hospital."

"Gagal jantung adalah sindrom progresif yang menyebabkan kualitas hidup yang buruk bagi pasien. Insidensi dan prevalensi gagal jantung terus meningkat. Saat ini, banyak bukti menunjukkan bahwa gagal jantung kronis dikarakteristikkan oleh aktivitas kompensasi neurohormonal yang berlebihan, termasuk overaktivitas simpatis yang kemudian menjadi landasan terapi. Diperlukan penatalaksanaan yang holistik dan komprehensif meliputi modifikasi gaya hidup, diet, serta intervensi farmakologi. Beberapa penelitian klinis menunjukkan bahwa akupunktur memiliki efek terapeutik dan modulatoris pada kondisi yang menjadi faktor risiko gagal jantung. Salah satu modalitas akupunktur adalah elektroakupunktur yang dapat menurunkan aktivitas simpatis dan menghambat respon reflek simpatoeksistoris kardiovaskuler. Penelitian ini merupakan uji klinis double blind randomized controlled trial (RCT), yang melibatkan 42 orang pasien gagal jantung dengan kriteria NYHA II-III, EF <40% terbagi dalam kelompok medikamentosa dan elektroakupunktur, medikamentosa dan elektroakupunktur sham, dan medikamentosa tanpa elektroakupunktur. Terapi dilakukan sebanyak 16 sesi selama 8 minggu. Pengukuran dilakukan pada awal terapi, pertengahan terapi, dan akhir terapi. Hasil menunjukkan pemberian elektroakupunktur pada terapi utama medikamentosa pada pasien gagal jantung mampu meningkatkan fraksi ejeksi, mean arterial pressure, dan menurunkan LVEDP lebih cepat, mempertahankan stabilitas dari heart rate variability, serta meningkatkan kualitas hidup yang diukur menggunakan uji jalan 6 menit secara signifikan.

---

Heart failure is a progressive syndrome that causes poor quality of life for patients. The incidence and prevalence of heart failure continues to increase. At present, much evidence shows that chronic heart failure is characterized by excessive neurohormonal compensatory activity, including sympathetic overactivity which later became the basis of therapy. Holistic and comprehensive management is needed including lifestyle modification, diet, and pharmacological interventions. Some clinical studies show that acupuncture has a therapeutic and modulator effect on conditions that are risk factors for heart failure. This study is a double blind clinical trial randomized controlled trial (RCT), involving 42 people with heart failure patients with NYHA II-III criteria, EF <40% divided into medical and electroacupuncture, medical and electroacupuncture sham, and medical without electroacupuncture groups. Therapy was done 16 sessions for 8 weeks. Measurements of the variables were carried out at the beginning of therapy, mid-therapy, and end of therapy. The results of showed that electroacupuncture in the top of guidlines medical therapy in heart failure patients were able to increase ejection fraction, mean arterial pressure, and to decrease LVEDP faster, maintain stability of heart rate variability, and improve quality of life measured using the 6 minute road test significantly."

"Latar Belakang: Gagal jantung merupakan salah satu penyebab kematian utama di Indonesia. Jantung dan ginjal berhubungan dengan erat yang dapat dijelaskan oleh sindrom kardiorenal. Saat ini, ada kekurangan data di rumah sakit tersier di Indonesia mengenai hubungan Ejection Fraction (EF) dengan fungsi ginjal. Metode: Penelitian ini merupakan penelitian cross-sectional yang mengikutsertakan pasien gagal jantung di RSUP Dr. Cipto Mangunkusomo tahun 2018 – 2020 sebagai populasi sasaran. Uji Chi-squared digunakan untuk menganalisis korelasi antar variabel. Izin etik diperoleh karena penelitian ini menggunakan manusia sebagai subjeknya. Hasil: Sebanyak 158 subjek diikutsertakan dalam penelitian ini setelah menerapkan kriteria inklusi dan eksklusi. Terdapat 37 (36,6%) pasien HF pada kelompok HFrEF yang memiliki eGFR stadium 3, 4, atau 5. Sedangkan di kelompok HFmrEF atau HFpEF, terdapat 29 (50,9%) dengan eGFR stadium 3, 4 , atau 5 (p-value = 0,115, RR = 0,72). Pasien gagal jantung dengan eGFR stadium 3, 4, atau 5 (n = 8;12,1%) dan eGFR stadium 1 atau 2 (n = 4; 4,3%) termasuk dalam kelompok NYHA kelas III atau IV (p-value = 0,125, RR = 2,79). Kesimpulan: Tidak ada perbedaan proporsi pasien HFrEF dengan HFpEF untuk memiliki eGFR stadium 3, 4, atau 5 serta proporsi pasien HF yang eGFR stadium 3,4 atau 5 dengan eGFR stadium 1 atau 2 untuk dimasukkan pada kelompok NYHA kelas III atau IV.

---

Background: Heart failure is considered one of leading cause of death In Indonesia. The heart and kidneys are tightly related which can be explained by the cardiorenal syndrome. There is a paucity of current data in a tertiary hospital in Indonesia regarding the association of Ejection Fraction (EF) with kidney function. Method: This is a cross-sectional study that includes heart failure patients in Dr. Cipto Mangunkusomo Hospital year 2018 – 2020 as the target population. The Chi-squared test is used to analyse the association between the variables. Ethical permission was obtained since this research used humans as the subject. Results: A total of 158 subjects were included in this study after applying the inclusion and exclusion criteria. There were 37 (36,6%) HF patients in the HFrEF group had eGFR stage 3, 4, or 5. Meanwhile, among HFmreEF or HFpEF group, there were 29 (50,9%) with eGFR stage 3, 4, or 5 (p-value = 0,115, RR = 0,72). HF patients in both eGFR stage 3, 4, or 5 (n = 8;12,1%) and eGFR stage 1 or 2 (n = 4; 4,3%) were included in the NYHA class III or IV group (p-value = 0,125, RR = 2,79). Conclusion: There are no differences in the proportion of HFrEF patients with HFpEF to have eGFR stage 3, 4, or 5 as well as in the proportion of HF patients whose eGFR stages 3,4 or 5 with eGFR stages 1 or 2 to be included in the NYHA class III or IV group. "